Inventor · disambiguated record
Michael R. Leadbetter
Also filed as: LEADBETTER MICHAEL · LEADBETTER MICHAEL R · LEADBETTER MICHAEL ROBERT
67 granted patents·12 pending applications·717 citations·filing 1989–2025
99Inventor score
Top patents by PatentIndex Score
79 records- 0198US6670376B1Aryl aniline β2 adrenergic receptor agonistsTHERAVANCE INC·Filed 2002·Granted Dec 30, 2003·129 cites·40 claims
- 0298US6635618B2Glycopeptide phosphonate derivativesTHERAVANCE INC·Filed 2001·Granted Oct 21, 2003·69 cites·31 claims
- 0397US7008923B2Glycopeptide phosphonate derivativesTHERAVANCE INC·Filed 2005·Granted Mar 7, 2006·16 cites·18 claims
- 0496US7351691B2Glycopeptide phosphonate derivativesTHERAVANCE INC·Filed 2006·Granted Apr 1, 2008·14 cites·15 claims
- 0596US7208471B2Glycopeptide phosphonate derivativesTHERAVANCE INC·Filed 2005·Granted Apr 24, 2007·24 cites·5 claims
- 0693US7700550B2Glycopeptide phosphonate derivativesTHERAVANCE INC·Filed 2007·Granted Apr 20, 2010·6 cites·10 claims
- 0793US6887976B2Glycopeptide phosphonate derivativesTHERAVANCE INC·Filed 2003·Granted May 3, 2005·24 cites·14 claims
- 0893US6872701B2Glycopeptide phosphonate derivativesTHERAVANCE INC·Filed 2003·Granted Mar 29, 2005·23 cites·20 claims
- 0993US6444786B1Glycopeptide derivatives and pharmaceutical compositions containing the sameADVANCED MEDICINE INC·Filed 2000·Granted Sep 3, 2002·41 cites·32 claims
- 1092US8101575B2Glycopeptide phosphonate derivativesLEADBETTER MICHAEL R·Filed 2010·Granted Jan 24, 2012·5 cites·3 claims
- 1192US6620781B2Glycopeptide carboxy-saccharide derivativesTHERAVANCE INC·Filed 2001·Granted Sep 16, 2003·27 cites·26 claims
- 1292US6455669B1Glycopeptide derivatives and pharmaceutical compositions containing the sameTHERAVANCE INC·Filed 2000·Granted Sep 24, 2002·34 cites·29 claims
- 1392US6392012B1Glycopeptide derivatives and pharmaceutical compositions containing the sameADVANCED MEDICINE INC·Filed 1999·Granted May 21, 2002·70 cites·36 claims
- 1491US8541448B2Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disordersCHARMOT DOMINIQUE·Filed 2011·Granted Sep 24, 2013·6 cites·6 claims
- 1590US7301004B2Process for preparing glycopeptide phosphonate derivativesTHERAVANCE INC·Filed 2006·Granted Nov 27, 2007·5 cites·14 claims
- 1689US9408840B2Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorderARDELYX INC·Filed 2015·Granted Aug 9, 2016·6 cites·6 claims
- 1789US7728104B2Process for preparing glycopeptide phosphonate derivativesTHERAVANCE INC·Filed 2007·Granted Jun 1, 2010·6 cites·17 claims
- 1888US10543207B2Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disordersARDELYX INC·Filed 2017·Granted Jan 28, 2020·3 cites·43 claims
- 1987US10376481B2Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disordersARDELYX INC·Filed 2017·Granted Aug 13, 2019·3 cites·32 claims
- 2087US8969377B2Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disordersARDELYX INC·Filed 2013·Granted Mar 3, 2015·3 cites·7 claims
- 2186US10968246B2Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonistsARDELYX INC·Filed 2019·Granted Apr 6, 2021·2 cites·27 claims
- 2286US8916569B2Compounds and methods for inhibiting phosphate transportARDELYX INC·Filed 2013·Granted Dec 23, 2014·7 cites·44 claims
- 2386US8809339B2Compounds and methods for inhibiting phosphate transportARDELYX INC·Filed 2013·Granted Aug 19, 2014·8 cites·36 claims
- 2486US7265086B2Glycopeptide carboxy-saccharide derivativesTHERAVANCE INC·Filed 2006·Granted Sep 4, 2007·5 cites·13 claims
- 2586US7157554B2Glycopeptide carboxy-saccharide derivativesTHERAVANCE INC·Filed 2005·Granted Jan 2, 2007·8 cites·20 claims
- 2686US6979723B2Process for preparing glycopeptide phosphonate derivativesTHERAVANCE INC·Filed 2002·Granted Dec 27, 2005·13 cites·24 claims
- 2785US8815910B2Compounds and methods for inhibiting phosphate transportARDELYX INC·Filed 2013·Granted Aug 26, 2014·7 cites·38 claims
- 2885US8815908B2Compounds and methods for inhibiting phosphate transportARDELYX INC·Filed 2013·Granted Aug 26, 2014·7 cites·32 claims
- 2985US7582765B2Aryl aniline β2 adrenergic receptor agonistsTHERAVANCE INC·Filed 2007·Granted Sep 1, 2009·2 cites·16 claims
- 3085US7405199B2Cross-linked glycopeptide-cephalosporin antibioticsTHERAVANCE INC·Filed 2005·Granted Jul 29, 2008·5 cites·6 claims
- 3184US11318129B2Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disordersARDELYX INC·Filed 2020·Granted May 3, 2022·1 cites·19 claims
- 3284US8106232B23-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonistsTRAPP SEAN G·Filed 2008·Granted Jan 31, 2012·5 cites·17 claims
- 3384US8101791B2Aminotetralin compounds as mu opioid receptor antagonistsLEADBETTER MICHAEL R·Filed 2008·Granted Jan 24, 2012·5 cites·16 claims
- 3483US10385024B2Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disordersARDELYX INC·Filed 2018·Granted Aug 20, 2019·3 cites·36 claims
- 3583US8153686B2Amino- and amido-aminotetralin derivatives and related compounds as mu opioid receptor antagonistsTRAPP SEAN G·Filed 2009·Granted Apr 10, 2012·6 cites·14 claims
- 3683US6903070B2Glycopeptide carboxy-saccharide derivativesTHERAVANCE INC·Filed 2003·Granted Jun 7, 2005·9 cites·14 claims
- 3782US7074890B2Process for preparing glycopeptide phosphonate derivativesTHERAVANCE INC·Filed 2004·Granted Jul 11, 2006·11 cites·14 claims
- 3881US12016856B2Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disordersARDELYX INC·Filed 2022·Granted Jun 25, 2024·0 cites·2 claims
- 3981US9006281B2Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disordersARDELYX INC·Filed 2013·Granted Apr 14, 2015·1 cites·15 claims
- 4081US8314128B2Aminotetralin compounds as mu opioid receptor antagonistsLEADBETTER MICHAEL R·Filed 2011·Granted Nov 20, 2012·4 cites·9 claims
- 4180US10392413B2Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonistsARDELYX INC·Filed 2016·Granted Aug 27, 2019·3 cites·39 claims
- 4280US8093354B2Process for preparing glycopeptide phosphonate derivativesLEADBETTER MICHAEL R·Filed 2010·Granted Jan 10, 2012·1 cites·24 claims
- 4379US8030445B2Glycopeptide derivativeTHERAVANCE INC·Filed 2009·Granted Oct 4, 2011·1 cites·1 claims
- 4479US6355810B1Multibinding inhibitors of HMG-CoA reductaseADVANCED MEDICINE INC·Filed 1999·Granted Mar 12, 2002·25 cites·8 claims
- 4579US2025067907A1Compounds and methods for treating hyperkalemiaARDELYX INC·Filed 2024·Application pending·0 cites
- 4677US6518242B1Derivatives of glycopeptide antibacterial agentsTHERAVANCE INC·Filed 1999·Granted Feb 11, 2003·26 cites·18 claims
- 4777US5728650AHerbicidal aza bisphosphonic acids and compositions containing the sameZENECA LTD·Filed 1995·Granted Mar 17, 1998·24 cites·18 claims
- 4875US6962970B2Glycopeptide derivatives and pharmaceutical compositions containing the sameTHERAVANCE INC·Filed 2002·Granted Nov 8, 2005·4 cites·10 claims
- 4975US2023273354A1Glycyrrhetinic acid derivatives for treating hyperkalemiaARDELYX INC·Filed 2023·Application pending·0 cites
- 5074US7553971B2Aryl aniline β2 adrenergic receptor agonistsTHERAVANCE INC·Filed 2006·Granted Jun 30, 2009·1 cites·14 claims
Showing the top 50 of 79 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →